Omics

 Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Retrieved on: 
Thursday, March 7, 2024

The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.

Key Points: 
  • The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.
  • Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.
  • Maximizing efficacy, while preserving safety are key elements that Debiopharm is eager to assess throughout the clinical development of Debio 0123.
  • With the successful realization of these requirements, Debio 0123 could become the first choice WEE1 inhibitor.

Mobile Phone Insurance Market Set to Surge to $56.56 Billion by 2028 with Trends in Cybersecurity and AI Integration Shaping the Industry

Retrieved on: 
Monday, March 4, 2024

The rising adoption of smartphones is expected to significantly drive the expansion of the mobile phone insurance market in the coming years.

Key Points: 
  • The rising adoption of smartphones is expected to significantly drive the expansion of the mobile phone insurance market in the coming years.
  • A reliable mobile phone insurance plan offers coverage for necessary repairs or replacements, fueling the growth of the mobile phone insurance market alongside the increasing smartphone adoption.
  • This surge in smartphone adoption is a key factor propelling the growth trajectory of the mobile phone insurance market.
  • Thus, the escalating frequency of phone theft incidents serves as a driving force behind the growth of the mobile phone insurance market.

Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024

Retrieved on: 
Friday, February 2, 2024

As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health.

Key Points: 
  • As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health.
  • Its offerings are designed to provide differentiated capabilities, providing customers with tools needed for success in precision medicine and beyond.
  • Dr. Alan Fletcher, Revvity’s senior vice president, life sciences, stated, "We're here in our backyard showing how we're seamlessly bringing it all together, powering innovation from research to reality.
  • Revvity will be exhibiting a selection of its extensive range of life sciences and diagnostics products and services.

Moa Reveals Data on Next-Generation Herbicides with New Modes of Action and Progress Towards Field Trials

Retrieved on: 
Thursday, January 25, 2024

The trials planned in the northern and southern hemispheres will cover multiple lead molecules derived from new herbicide modes of action (MOAs).

Key Points: 
  • The trials planned in the northern and southern hemispheres will cover multiple lead molecules derived from new herbicide modes of action (MOAs).
  • Herbicide-resistant weeds threaten food security and agricultural productivity, and are a major problem for growing numbers of farmers across the world.
  • “The need for innovation to develop next-generation herbicides to overcome weed resistance to current herbicides is becoming ever more apparent,” says Dr Xavier Jacq, Chief Scientific Officer of Moa Technology.
  • At Moa we are advancing a growing pipeline of novel herbicides including bioherbicides towards field trials at pace.

Betteromics Raises $20 Million in Series A Financing, Led by Sofinnova Partners and Triatomic Capital

Retrieved on: 
Thursday, October 26, 2023

Betteromics which has developed a clinical-grade compliant Software-as-a-Service platform that empowers life sciences professionals with the latest AI and computational techniques, announced that it has raised $20 million in a Series A financing led by Sofinnova Partners and Triatomic Capital, with participation from SHAKTI.

Key Points: 
  • Betteromics which has developed a clinical-grade compliant Software-as-a-Service platform that empowers life sciences professionals with the latest AI and computational techniques, announced that it has raised $20 million in a Series A financing led by Sofinnova Partners and Triatomic Capital, with participation from SHAKTI.
  • The financing will expand the Betteromics team, and scale marketing and sales efforts to life science companies, ranging from startups to the largest enterprises.
  • Jeff Huber, Partner at Triatomic Capital, said: "The most meaningful application of AI technology is in life sciences.
  • Edward Kliphuis, Partner at Sofinnova Partners, said: "Betteromics uniquely merges data science and human expertise in life sciences.

2023 Annual Single Cell-Omics Conference: Breaking Barriers in Biomedical Research - Explore Single-Cell Omics Innovations (London, United Kingdom - October 9-10, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023

The "2nd Annual Single Cell-Omics Conference" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2nd Annual Single Cell-Omics Conference" conference has been added to ResearchAndMarkets.com's offering.
  • The conference will assimilate diverse sessions on a broad perspective of novel research and development in the field of multi-omics research.
  • The fundamentals of Single Cell have proven to be an indispensable resource in the sphere of medical research and new diagnostic strategies.
  • Thus, these single cell omics prospects are much anticipated to revolutionise our adequacy to understand the magnitude of omics diversity occurring in our biological systems.

New Fuuz Website Helps Manufacturers and Distributors find Technology Solutions to Improve Industry Processes

Retrieved on: 
Wednesday, March 29, 2023

AUBURN HILLS, Mich., March 29, 2023 /PRNewswire-PRWeb/ -- Fuuz™ powered by MFGx, an anything Platform as a Service (xPaaS) solution built for industry, today unveiled a new website that makes it easier to find technologies that solve complex operational problems.

Key Points: 
  • The new site provides detailed information about how Fuuz can improve industry processes, such as manufacturing execution, warehouse management, production monitoring and more.
  • The new site provides detailed information about how Fuuz can improve industry processes, such as manufacturing execution, warehouse management, production monitoring and more.
  • "The Fuuz platform is unlike anything on the market," said Craig Scott, founder and CEO of Fuuz.
  • "It was built for industry, with capabilities to address the challenges of manufacturers and distributors globally–all ready to go on Day One."

EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb

Retrieved on: 
Thursday, March 16, 2023

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
  • Evotec and Bristol Myers Squibb entered their strategic protein degradation partnership in 2018 and expanded it in May of 2022, because of the highly productive initial collaboration generating a promising pipeline.
  • Since the expansion, Evotec has significantly scaled up its activities to develop highly promising compounds from Bristol Myers Squibb’s industry-leading library of cereblon E3 ligase modulators (“CELMoDs™”).
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “The recent extension and expansion of our partnership with BMS continues to deliver high value programs.

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development

Retrieved on: 
Wednesday, January 25, 2023

The company plans to continue growing its team to power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases.

Key Points: 
  • The company plans to continue growing its team to power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases.
  • "We are thrilled to announce the addition of Neil, Gayathri, Mo and Eddie to the team.
  • The senior management team contributes extensive industry knowledge and leadership in biologics drug discovery and development, data science, and business development.
  • Gayathri Swaminath, PhD, MBA , Senior Vice President of Discovery, brings over 17 years of preclinical and translational research and drug development experience.

Slone Partners Places Gayarthri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics

Retrieved on: 
Wednesday, February 8, 2023

SOUTH RIDING, Va., Feb. 8, 2023 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Edward Moler, PhD as Vice President of Data Science and Gayathri Swaminath, PhD, MBA as Senior Vice President of Discovery at Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins.

Key Points: 
  • Gayathri Swaminath, PhD, MBA brings more than 17 years of preclinical and translational research and drug development experience.
  • Edward Moler, PhD brings more than 20 years of experience in bioinformatics, predictive modeling, biomarker and diagnostics discovery, machine learning, Omics, cell-based assay technology, and automation.
  • "Gayathri Swaminath and Eddie Moler are both highly accomplished and respected thinkers and leaders in drug discovery and development and data science with a truly impressive depth of knowledge," said Slone Partners President Tara Kochis .
  • Edward Moler received a PhD in Chemistry from UC Berkeley and a BS in Chemistry from Texas A&M University.